Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells

Joseph W. Fay, A. Karolina Palucka, Sophie Paczesny, Madhav Dhodapkar, Dennis A. Johnston, Susan Burkeholder, Hideki Ueno, Jacques Banchereau

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2-83), and the median event-free survival was 7 months (range: 2-83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs.

Original languageEnglish (US)
Pages (from-to)1209-1218
Number of pages10
JournalCancer Immunology Immunotherapy
Volume55
Issue number10
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Dendritic Cells
Melanoma
Peptides
Vaccination
Vaccines
Immunity
MART-1 Antigen
Neoplasm Metastasis
Langerhans Cells
Monophenol Monooxygenase
Human Influenza
Disease-Free Survival
Blood Cells
Lymph Nodes
Staining and Labeling
Survival
Liver

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. / Fay, Joseph W.; Palucka, A. Karolina; Paczesny, Sophie; Dhodapkar, Madhav; Johnston, Dennis A.; Burkeholder, Susan; Ueno, Hideki; Banchereau, Jacques.

In: Cancer Immunology Immunotherapy, Vol. 55, No. 10, 10.2006, p. 1209-1218.

Research output: Contribution to journalArticle

Fay, Joseph W. ; Palucka, A. Karolina ; Paczesny, Sophie ; Dhodapkar, Madhav ; Johnston, Dennis A. ; Burkeholder, Susan ; Ueno, Hideki ; Banchereau, Jacques. / Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells. In: Cancer Immunology Immunotherapy. 2006 ; Vol. 55, No. 10. pp. 1209-1218.
@article{afabfd601d9c4daab27570a8a07e2067,
title = "Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells",
abstract = "Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2-83), and the median event-free survival was 7 months (range: 2-83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs.",
author = "Fay, {Joseph W.} and Palucka, {A. Karolina} and Sophie Paczesny and Madhav Dhodapkar and Johnston, {Dennis A.} and Susan Burkeholder and Hideki Ueno and Jacques Banchereau",
year = "2006",
month = "10",
doi = "10.1007/s00262-005-0106-6",
language = "English (US)",
volume = "55",
pages = "1209--1218",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "10",

}

TY - JOUR

T1 - Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells

AU - Fay, Joseph W.

AU - Palucka, A. Karolina

AU - Paczesny, Sophie

AU - Dhodapkar, Madhav

AU - Johnston, Dennis A.

AU - Burkeholder, Susan

AU - Ueno, Hideki

AU - Banchereau, Jacques

PY - 2006/10

Y1 - 2006/10

N2 - Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2-83), and the median event-free survival was 7 months (range: 2-83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs.

AB - Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2-83), and the median event-free survival was 7 months (range: 2-83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs.

UR - http://www.scopus.com/inward/record.url?scp=33745603724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745603724&partnerID=8YFLogxK

U2 - 10.1007/s00262-005-0106-6

DO - 10.1007/s00262-005-0106-6

M3 - Article

C2 - 16331519

AN - SCOPUS:33745603724

VL - 55

SP - 1209

EP - 1218

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 10

ER -